
1. General Information
Bryxta 300 mg Injection belongs to the class of anti-angiogenic monoclonal antibodies. Its active ingredient, bevacizumab, is used as part of treatment for several cancers, generally in combination with other anticancer medicines depending on the cancer type and treatment protocol. It is a prescription-only medicine and must be administered by qualified healthcare professionals.
For Phoenix Exim, product information can be presented as:
Product: Bryxta 300 mg Injection
Active ingredient: Bevacizumab 300 mg
Dosage form: Solution for intravenous infusion
Pack: 300 mg/12 mL vial
Therapeutic category: Anticancer / monoclonal antibody
Manufacturer/Marketer: Zydus Lifesciences
Origin: India
2. Product Information
Bevacizumab is a recombinant monoclonal antibody that targets vascular endothelial growth factor (VEGF). Bryxta 300 mg is supplied as an intravenous infusion and requires appropriate medical supervision, including monitoring for infusion reactions and other treatment-related complications.
The product should generally be stored under refrigeration at 2°C–8°C and should not be frozen. Proper cold-chain handling is important for maintaining the quality of the biologic medicine.
3. Uses of Bryxta 300 mg Injection
Depending on the patient's cancer type and approved treatment regimen, bevacizumab may be used for:
- Metastatic colorectal cancer
- Non-small-cell lung cancer
- Advanced or metastatic kidney cancer
- Cervical cancer
- Ovarian, fallopian-tube and primary peritoneal cancers
- Certain cases of recurrent/progressive glioblastoma
- Certain metastatic breast-cancer treatment regimens
It is frequently used in combination with chemotherapy or other anticancer treatments, rather than as a standalone treatment. The exact indication and combination depend on the patient's diagnosis and local prescribing guidelines.
4. Benefits of This Medicine
The principal therapeutic benefit of bevacizumab is its ability to inhibit the formation of new blood vessels that supply tumors.
By blocking VEGF, the medicine can reduce the tumor's access to oxygen and nutrients. This can help slow tumor growth and, in appropriate treatment regimens, improve disease control when used with other anticancer therapies.
The expected benefit varies considerably according to the cancer type, stage, treatment combination and individual patient response.
5. Side Effects
Like other anticancer medicines, Bryxta 300 mg can cause adverse effects. Some patients may experience:
- Nosebleeds
- High blood pressure
- Headache
- Protein in the urine
- Bleeding or hemorrhage
- Taste changes
- Back pain
- Dry skin
- Nasal inflammation
- Gastrointestinal symptoms
- Infusion-related reactions
Bevacizumab can also cause serious complications, including significant bleeding, gastrointestinal perforation, blood clots, severe hypertension and impaired wound healing.
6. Common Side Effects
Commonly reported effects include:
- Nosebleeds
- Headache
- High blood pressure
- Nasal inflammation/rhinitis
- Protein in urine
- Taste changes
- Dry skin
- Bleeding
- Back pain
- Increased tearing/lacrimation
Patients should inform their healthcare provider if side effects are persistent, severe or unusual.
7. How to Use
Bryxta 300 mg Injection must not be self-administered.
It is administered by a doctor or trained healthcare professional as a slow intravenous infusion. The dosage, infusion interval and duration of therapy depend on the cancer being treated and the patient's response.
The first infusion may be administered more slowly, with subsequent infusion times potentially adjusted if it is well tolerated. It should not be administered as an IV push or bolus.
8. How This Medicine Works
Bryxta contains bevacizumab, which binds to VEGF (vascular endothelial growth factor).
VEGF promotes the development of new blood vessels. Tumors can use these new blood vessels to obtain oxygen and nutrients needed for growth.
By blocking VEGF, bevacizumab helps inhibit tumor-associated blood-vessel formation, thereby helping to slow tumor growth and progression in appropriate cancers.
9. Safety Advice
- Use only under the supervision of an oncologist or qualified healthcare professional.
- Tell your doctor about any history of high blood pressure, bleeding disorders, blood clots, gastrointestinal problems or heart problems.
- Blood pressure and urine protein may need regular monitoring during treatment.
- Tell your doctor before planned surgery because bevacizumab can interfere with wound healing. Major surgery generally requires appropriate treatment interruption and adequate wound healing before restarting therapy.
- Seek urgent medical attention for severe bleeding, severe abdominal pain, chest pain, difficulty breathing or neurological symptoms.
- Bevacizumab can harm a fetus; effective contraception is recommended during treatment and for an appropriate period after treatment according to prescribing guidance.
- Breastfeeding is generally not recommended during treatment and for the recommended period after the final dose.
- Store refrigerated at 2°C–8°C and do not freeze. Maintain appropriate cold-chain conditions during transportation.
10. FAQs
Q1. What is Bryxta 300 mg Injection used for?
It is a bevacizumab-containing anticancer medicine used for several cancers, including colorectal, lung, kidney, cervical and certain ovarian/peritoneal cancers, depending on the approved treatment regimen.
Q2. What is the active ingredient in Bryxta 300 mg?
The active ingredient is bevacizumab 300 mg.
Q3. How is Bryxta 300 mg administered?
It is administered by a healthcare professional through intravenous infusion. It should not be self-injected.
Q4. Can Bryxta 300 mg be used alone?
Depending on the indication, bevacizumab may be used alone or alongside other anticancer therapies. The appropriate regimen must be determined by the treating oncologist.
Q5. Does Bryxta 300 mg require refrigeration?
Yes. Product information specifies refrigerated storage at approximately 2°C–8°C and advises not to freeze it.
Q6. Can pregnant women use Bryxta 300 mg?
Bevacizumab can cause fetal harm and is generally contraindicated during pregnancy. Patients who could become pregnant should discuss effective contraception with their doctor.
Q7. What should I do if I miss a scheduled infusion?
Contact the treating healthcare team. Do not attempt to compensate for a missed dose yourself.
11. Substitutes for Bryxta 300 mg
Potential alternatives are generally other bevacizumab products with the same strength and dosage form, but substitution should be confirmed by a doctor or pharmacist.
Examples of bevacizumab brands/products may include Avastin and other approved bevacizumab biosimilars or branded equivalents. The appropriate product depends on the indication, strength, regulatory approval and availability in the destination country.
A substitute should not be selected based solely on the brand name or price; the active ingredient, strength, formulation, regulatory status and patient's treatment plan should all be verified.
12. SEO & B2B Keywords
For Phoenix Exim – Nagpur, India, you can use keywords such as:
- Bryxta 300 mg Injection exporter from India
- Bryxta 300 mg Bevacizumab Injection supplier
- Buy Bryxta 300 mg Injection from India
- Bryxta 300 mg wholesale supplier India
- Bevacizumab 300 mg Injection exporter
- Bevacizumab 300 mg pharmaceutical supplier India
- Bryxta 300 mg Injection wholesale
- Bryxta 300 mg Injection international supplier
- Bryxta 300 mg Injection export from Nagpur
- Bevacizumab Injection exporter from Nagpur India
- Bryxta 300 mg Injection supplier USA
- Bryxta 300 mg Injection supplier UK
- Bryxta 300 mg Injection supplier Australia
- Bryxta 300 mg Injection supplier Canada
- Bryxta 300 mg Injection supplier Singapore
- Bryxta 300 mg Injection supplier South Korea
- Bryxta 300 mg Injection supplier UAE
- Bevacizumab 300 mg Injection supplier USA
- Bevacizumab 300 mg Injection supplier UK
- Bevacizumab 300 mg Injection supplier Australia
- Bevacizumab 300 mg Injection supplier Canada
- Bevacizumab 300 mg Injection supplier Singapore
- Bevacizumab 300 mg Injection supplier South Korea
- Bevacizumab 300 mg Injection supplier UAE
- Anti-cancer medicine exporter India
- Oncology medicine exporter from Nagpur
- Zydus Bevacizumab 300 mg supplier India
- Bryxta 300 mg 12 mL Injection supplier
- Bevacizumab oncology medicine wholesale India
- Phoenix Exim pharmaceutical exporter Nagpur India
Keywords







